NRx Pharmaceuticals (NASDAQ:NRXP) Given “Buy” Rating at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of NRx Pharmaceuticals (NASDAQ:NRXP) in a report released on Tuesday morning,Benzinga reports. They currently have a $31.00 price objective on the stock.

NRXP has been the topic of several other reports. Ascendiant Capital Markets raised their target price on shares of NRx Pharmaceuticals from $44.00 to $45.00 and gave the stock a “buy” rating in a research report on Monday, December 2nd. EF Hutton Acquisition Co. I upgraded shares of NRx Pharmaceuticals to a “strong-buy” rating in a report on Monday, October 21st. Finally, HC Wainwright restated a “buy” rating and set a $19.00 price objective on shares of NRx Pharmaceuticals in a report on Monday, November 25th.

NRx Pharmaceuticals Trading Up 43.8 %

Shares of NASDAQ:NRXP opened at $2.20 on Tuesday. The firm has a market cap of $26.61 million, a price-to-earnings ratio of -1.03 and a beta of 1.25. The stock’s 50-day moving average price is $1.31 and its two-hundred day moving average price is $1.76. NRx Pharmaceuticals has a 12-month low of $1.10 and a 12-month high of $7.33.

Insider Activity at NRx Pharmaceuticals

In other NRx Pharmaceuticals news, Chairman Jonathan C. Javitt purchased 40,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 17th. The stock was purchased at an average cost of $1.17 per share, with a total value of $46,800.00. Following the transaction, the chairman now owns 84,634 shares in the company, valued at approximately $99,021.78. This trade represents a 89.62 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. 19.00% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in NRx Pharmaceuticals stock. Townsquare Capital LLC bought a new stake in shares of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) during the 3rd quarter, according to its most recent filing with the SEC. The firm bought 15,041 shares of the company’s stock, valued at approximately $25,000. Townsquare Capital LLC owned 0.14% of NRx Pharmaceuticals as of its most recent filing with the SEC. 4.27% of the stock is currently owned by institutional investors.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.